Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-08-02
DOI
10.3389/fphar.2021.577263
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- WS19.3 Bidirectional pharmacokinetic interactions between ivacaftor and lumacaftor
- (2020) P. Hanafin et al. Journal of Cystic Fibrosis
- Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis
- (2020) Marsha Tan et al. Magnetochemistry
- Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis
- (2019) Elena K. Schneider-Futschik GENE THERAPY
- Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype
- (2019) Yuan Zhou et al. Multiple Sclerosis Journal
- Metabolomic Analysis by Nuclear Magnetic Resonance Spectroscopy as a New Approach to Understanding Inflammation and Monitoring of Pharmacological Therapy in Children and Young Adults With Cystic Fibrosis
- (2018) Paolo Montuschi et al. Frontiers in Pharmacology
- Predictive factors for lumacaftor/ivacaftor clinical response
- (2018) Alexandra Masson et al. Journal of Cystic Fibrosis
- PharmGKB summary
- (2017) Alison E. Fohner et al. Pharmacogenetics and Genomics
- Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
- (2017) Elena K. Schneider et al. Jove-Journal of Visualized Experiments
- Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
- (2016) EK Schneider et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis
- (2016) Emma D. Deeks DRUGS
- A safety evaluation of ivacaftor for the treatment of cystic fibrosis
- (2016) Susanna A. McColley Expert Opinion On Drug Safety
- Development of HPLC and LC–MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO
- (2016) Elena K. Schneider et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Cystic fibrosis
- (2016) J Stuart Elborn LANCET
- The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression
- (2015) Steven L Dubovsky Expert Opinion on Drug Metabolism & Toxicology
- Nuclear Magnetic Resonance–based Metabolomics Discriminates Primary Ciliary Dyskinesia from Cystic Fibrosis
- (2014) Paolo Montuschi et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein
- (2014) Sarah M. Robertson et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ivacaftor for patients with cystic fibrosis
- (2014) Claire E Wainwright Expert Review of Respiratory Medicine
- Grapefruit-Drug Interactions
- (2010) Kay Seden et al. DRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now